Important new data for the antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) have been outlined ahead of their presentation at the annual meet 5 September 2022
The annual meeting of the European Society of Medical Oncology (ESMO) kicks off in Paris on 9 September.and early indications are the event could be full of pra 29 August 2022
At the annual breast cancer congress of the European Society of Medical Oncology (ESMO), Swiss pharma giant Novartis has announced updated median overall surviv 4 May 2022
Data from the Phase III IMpower010 trial testing Tecentriq (atezolizumab) after surgery and chemo in lung cancer show a 34% reduction in the risk of disease rec 21 September 2021
Bristol Myers Squibb’s immuno-oncology combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to deliver mixed results, according to data shared at 20 September 2021
US epigenetic therapies company Epizyme has presented new data on its approved product, Tazverik (tazemetostat), at the European Society for Medical Oncology (E 20 September 2021
Positive results from a Phase III trial of OSE Immunotherapeutics’ neoepitope-based cancer vaccine Tedopi (OSE: 2101) lifted shares in the company by 20% on Mon 20 September 2021
US oncology specialist Mirati Therapeutics was trading 8% higher in early pre-market trading on Monday after presenting results at the European Society for Medi 20 September 2021
At the annual congress of the European Society of Medical Oncology (ESMO), Swiss drugmaker Novartis has announced important new data for its CDK4/6 inhibitor Ki 20 September 2021
At the annual congress of the European Society of Medical Oncology (ESMO 2021), Japan’s Astellas Pharma and partner Pfizer are offering new data for Xtandi (enz 17 September 2021
Canada’s Zymeworks, a specialist in multifunctional biologics, has announced new Phase II data for its HER2-targeting antibody zanidatamab. 17 September 2021
From the 2021 annual congress of the European Society of Medical Oncology (ESMO), there is new data for a combo of Cabometyx (cabozantinib) and Opdivo (nivoluma 17 September 2021
Californian antiviral specialist Gilead Sciences has announced new data from the Phase III ASCENT study of its antibody-drug conjugate (ADC) Trodelvy (sacituzum 17 September 2021
US biotech Amgen could be closing in on another indication for its KRAS inhibitor Lumakras (sotorasib), which won US approval in a form of lung cancer in May of 17 September 2021
Bristol Myers Squibb is to present new three-year data from the CheckMate-743 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) at the European Society of Me 15 September 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.